Antituberculous Treatment Itself Might Prevent Visual Impairment in Presumed Tuberculosis-Related Uveitis

REFERENCES

• Situació epidemiológica i tendència de l’endèmia tuberculosa a Catalunya. Informe anual 2015. Agència de salut pública de Catalunya. Departament de Salut, Generalitat de Catalunya. Website Operator. http://canalsalut.gencat.cat/web/.content/contingut_responsiu/salutAZ/T/tuberculosi/documents_prof/arxius/informe_anual_tuberculosi_2015.pdf. Published November, 2016. Accessed July 8, 2018.
   Google Scholar
• Jakob E, Reuland MS, Mackensen F, et al. Uveitis subtypes in a German interdisciplinary uveitis center-analysis of 1916 patients. J Rheumatol. 2009;36(1):127–136. doi:10.3899/jrheum.080102.
   PubMed Web of Science ®Google Scholar
• Llorenç V, Mesquida M, Sainz de la Maza M, et al. Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization. Acta Ophthalmol. 2015;93(6):561–567. doi:10.1111/aos.12675.
   PubMed Web of Science ®Google Scholar
• Gupta A, Bansal R, Gupta V, Sharma A, Bambery P. Ocular signs predictive of tubercular uveitis. Am J Ophthalmol. 2010;149(4):562–570. doi:10.1016/j.ajo.2009.11.020.
   PubMed Web of Science ®Google Scholar
• Yeh S, Sen HN, Colyer M, Zapor M, Wroblewski K. Update on ocular tuberculosis. Curr Opin Ophthalmol. 2012;23(6):551–556. doi:10.1097/ICU.0b013e328358ba01.
   PubMed Web of Science ®Google Scholar
• Gupta V, Gupta A, Rao NA. Intraocular tuberculosis – an update. Surv Ophthalmol. 2007;52(6):561–587. doi:10.1016/j.survophthal.2007.08.015.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working groupstandardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Jakob E, Max R, Zimmermann S, et al. Three years of experience with QuantiFERON-TB gold testing in patients with uveitis. Ocul Immunol Inflamm. 2014;22(6):478–484. doi:10.3109/09273948.2013.866255.
   PubMed Web of Science ®Google Scholar
• Patel SS, Saraiya NV, Tessler HH, Goldstein DA. Mycobacterial ocular inflammation: delay in diagnosis and other factors impacting morbidity. JAMA Ophthalmol. 2013;131(6):752–758. doi:10.1001/jamaophthalmol.2013.71.
   PubMed Web of Science ®Google Scholar
• Tognon MS, Fiscon M, Mirabelli P, et al. Tuberculosis of the eye in Italy: a forgotten extrapulmonary localization. Infection. 2014;42(2):335–342. doi:10.1007/s15010-013-0554-4.
   PubMed Web of Science ®Google Scholar
• Gunasekeran DV, Gupta B, Cardoso J, Pavesio CE, Agrawal R. Visual morbidity and ocular complications in presumed intraocular tuberculosis: an analysis of 354 cases from a non-endemic population. Ocul Immunol Inflamm. 2017;20:1–5. doi:10.1080/09273948.2017.1296580.
   Web of Science ®Google Scholar
• La Distia Nora R, van Velthoven ME, Ten Dam-van Loon NH, et al. Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis. Am J Ophthalmol. 2014;157(4):754–761. doi:10.1016/j.ajo.2013.11.013.
   PubMed Web of Science ®Google Scholar
• Damato EM, Dawson S, Liu X, et al. A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis. J Ophthalmic Inflamm Infect. 2017;7(1):23. doi:10.1186/s12348-017-0141-4.
   PubMed Web of Science ®Google Scholar
• Sanghvi C, Bell C, Woodhead M, Hardy C, Jones N. Presumed tuberculous uveitis: diagnosis, management, and outcome. Eye (Lond). 2011;25(4):475–480. doi:10.1038/eye.2010.235.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gunasekeran DV, Grant R, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1. JAMA Ophthalmol. 2017;135(12):1318–1327. doi:10.1001/jamaophthalmol.2017.4485.
   PubMed Web of Science ®Google Scholar
• Hamade IH, Tabbara KF. Complications of presumed ocular tuberculosis. Acta Ophthalmol. 2010;88(8):905–909. doi:10.1111/j.1755-3768.2009.01579.x.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gupta V, Arora S, Dogra MR, Bambery P. PCR-positive tubercular retinal vasculitis: clinical characteristics and management. Retina. 2001;21:435–444.
   PubMed Web of Science ®Google Scholar
• Brunner DR, Zweifel SA, Barthelmes D, Meier F, Böni C. Review of people with retinal vasculitis and positive QuantiFERON-TB gold test in an area nonendemic for tuberculosis. Int Ophthalmol. 2017. Epub ahead of print. doi:10.1007/s10792-017-0739-4.
   PubMed Web of Science ®Google Scholar
• Manousaridis K, Ong E, Stenton C, Gupta R, Browning AC, Pandit R. Clinical presentation, treatment, and outcomes in presumed intraocular tuberculosis: experience from Newcastle upon Tyne, UK. Eye (Lond). 2013;27(4):480–486. doi:10.1038/eye.2013.11.
   PubMed Web of Science ®Google Scholar
• Agrawal R, Gunasekeran DV, Gonzalez-Lopez JJ, et al. Peripheral retinal vasculitis: analysis of 110 consecutive cases and a contemporary reappraisal of tubercular etiology. Retina. 2017;37(1):112–117. doi:10.1097/IAE.0000000000001239.
   PubMed Web of Science ®Google Scholar
• Gunasekeran DV, Agrawal R, Agarwal A, et al. The collaborative ocular tuberculosis study (COTS)-1: a multinational review of 251 patients with tubercular retinal vasculitis. Retina. 2018. [ Epub ahead of print]. doi:10.1097/IAE.0000000000002194.
   PubMed Web of Science ®Google Scholar
• Kee AR, Gonzalez-Lopez JJ, Al-Hity A, et al. Anti-tubercular therapy for intraocular tuberculosis: a systematic review and meta-analysis. Surv Ophthalmol. 2016;61(5):628–653. doi:10.1016/j.survophthal.2016.03.001.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Leong BCS, Zhang X, Lightman S, McCluskey PJ. Sydney-London latent ocular TB study group. Effect of antituberculous therapy on uveitis associated with latent tuberculosis. Am J Ophthalmol. 2018;190:164–170. doi:10.1016/j.ajo.2018.03.032.
   PubMed Web of Science ®Google Scholar
• Ang L, Kee A, Yeo TH, et al. Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore. Int Ophthalmol. 2018;38(1):11–18. doi:10.1007/s10792-016-0401-6.
   PubMed Web of Science ®Google Scholar
• Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case-control study. Br J Ophthalmol. 2012;96(3):332–336. doi:10.1136/bjophthalmol-2011-300209.
   PubMed Web of Science ®Google Scholar
• Namasivayam S, Maiga M, Yuan W, et al. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome. 2017;5(1):71. doi:10.1186/s40168-017-0286-2.
   PubMed Web of Science ®Google Scholar
• Maji A, Misra R, Dhakan DB, et al. Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers. Environ Microbiol. 2018;20(1):402–419. doi:10.1111/1462-2920.14015.
   PubMed Web of Science ®Google Scholar